Amarin Corporation PLC Stock News

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product suppl

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses.

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product suppl

Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief

15 Jun 2020 - The Australian share market is set to open higher this morning after Wall Street rebounded on Friday. Technology and financial stocks led the recovery. Coronavirus developments will be f

Apex health bodies across the world, including the Centers for Disease Control and Prevention, have in the last couple of months included loss of smell among the list of COVID symptoms.

India's drug regulator had on June 1 granted US pharma giant Gilead Sciences marketing authorisation for its drug remdesivir, being touted as a potential treatment for COVID-19, in the country.

The rollout of anti-coronavirus drug, remdesivir will take more time as pharmaceutical firms are working on providing safety and quality data for its production. The Union Health Ministry has recommen

Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an 'emergency use authorisation' (EUA) by the United States Food and Drug Administration (USFDA) to treat patients suffer

Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.

Drug firm Zydus Cadila on Friday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19.

The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol, sources in the know of the developments told PTI.

Anti-viral drug remdesivir and tocilizumab, an immunomodulator, are being considered for 'restricted use' on severely ill COVID-19 patients on 'emergency and compassionate grounds', according to revis

The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.